A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 May 2017
At a glance
- Drugs DCVAC LuCa (Primary)
- Indications Non-small cell lung cancer
- Focus First in man; Therapeutic Use
- Sponsors SOTIO
- 19 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.
- 19 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.
- 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.